<DOC>
	<DOCNO>NCT01292239</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TMC435 compare placebo combination peginterferon alfa-2a ( pegIFN alfa-2a ) ribavirin treatment-naive patient chronic genotype 1 hepatitis C virus ( HCV ) infection Japan .</brief_summary>
	<brief_title>A Phase III Study TMC435 Treatment-naive , Genotype 1 , Hepatitis C-infected Patients</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , 2-arm , double-blind study evaluate efficacy safety TMC435 ( also refer jnj-38733214-aaa ) versus placebo combination standard care ( SoC ) therapy ( peginterferon alfa-2a [ pegIFN alfa-2a ] ribavirin ) adult treatment-na√Øve patient ( never receive treatment HCV ) chronic genotype 1 HCV infection Japan . The study objective evaluate compare efficacy TMC435 v placebo proportion patient undetectable HCV ribonucleic acid ( RNA ) . In TMC435 treatment group , patient receive 12 week treatment TMC435 ( 100 mg ) daily plus SoC follow additional 12 36 week treatment SoC . In placebo treatment group , patient receive 12 week treatment placebo daily plus SoC follow additional 36 week treatment SoC . TMC435 100-mg capsule take orally mouth . The SoC treatment give 24 48 week . Pegylated interferon supply vial contain 1.0 mL solution 180 mcg pegIFN alpha-2a administer subcutaneously ( injected syringe skin ) weekly . Ribavirin give 200-mg tablet ( daily dose : 600-1000 mg base body weight ) , take orally mouth two time day meal .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patient must chronic genotype 1 HCV infection HCV RNA level &gt; = 5.0 log10 IU/mL Patient never receive treatment HCV Patient must willing use contraceptive measure time inform consent 6 month last dose study medication Coinfection HCV genotype coinfection human immunodeficiency virus ( HIV ) Diagnosed hepatic cirrhosis hepatic failure A medical condition contraindication pegIFN ribavirin therapy History , current medical condition could impact safety patient study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viral RNA</keyword>
</DOC>